209 related articles for article (PubMed ID: 32318947)
1. ASO Author Reflections: To Redo or Not to Redo, That is the Question: Assessing the Slings and Arrows of Repeat CRS/HIPEC in Patients with Recurrent or Progressive Peritoneal Carcinomatosis.
Powers BD; Dineen SP
Ann Surg Oncol; 2020 Dec; 27(13):4892-4893. PubMed ID: 32318947
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: If Once Is Good, Is Twice Just as Good? A critical evaluation of Repeat CRS-HIPEC for Colorectal Peritoneal Metastases.
Laks S; Adileh M; Ben-Yaacov A; Nissan A
Ann Surg Oncol; 2021 Sep; 28(9):5339-5340. PubMed ID: 33604829
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Pathologic Response Ratio (PRR) in CRS and HIPEC for Peritoneal Metastasis from Colorectal Cancer.
Mor E; Laks S; Nissan A; Adileh M
Ann Surg Oncol; 2021 Dec; 28(13):9148-9149. PubMed ID: 34180017
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Characterizing the Peritoneal Immune Response to the Surgical and Thermal Trauma of Peritoneal Cytoreduction and HIPEC.
Franko J; Ferrel B; Gorvet M
Ann Surg Oncol; 2020 Dec; 27(13):5014-5015. PubMed ID: 32720041
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-Analysis.
Martins M; Santos-Sousa H; Araújo F; Nogueiro J; Sousa-Pinto B
Ann Surg Oncol; 2022 Nov; 29(12):7538-7539. PubMed ID: 35907988
[No Abstract] [Full Text] [Related]
6. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
7. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
8. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
[TBL] [Abstract][Full Text] [Related]
9. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
10. ASO Author Reflections: Palliative Management of Peritoneal Metastasis Exploring the Risks and Benefits of CRS/HIPEC, a Distinctly Different Context Than Early CRS/HIPEC Intervention With 'Curative Intent'.
Foster JM; Zhang C
Ann Surg Oncol; 2022 May; 29(5):3347-3348. PubMed ID: 35217972
[No Abstract] [Full Text] [Related]
11. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: If at First You Don't Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer.
Lopez-Ramirez F; King MC; Gushchin V; Sardi A
Ann Surg Oncol; 2022 Jun; 29(6):3402-3403. PubMed ID: 35015184
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: First Do No Harm-Revisiting Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Trials to Reduce the Risk of Peritoneal Metastasis.
Yurttas C; Königsrainer A; Löffler MW
Ann Surg Oncol; 2021 Dec; 28(13):9096-9097. PubMed ID: 34117575
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Thirty Years of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Wake Forest University.
Valenzuela CD; Levine EA; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3446-3447. PubMed ID: 35275327
[No Abstract] [Full Text] [Related]
15. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
[TBL] [Abstract][Full Text] [Related]
17. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U
Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994
[TBL] [Abstract][Full Text] [Related]
18. ASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Apr; 31(4):2511-2512. PubMed ID: 38219000
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Decoding the Complexities of Cytoreductive Surgery and HIPEC Procedural Billing: A Potential Blueprint for the Peritoneal Surface Malignancy Surgeon.
Abreu AA; Wang SC; Karagkounis G; Polanco PM
Ann Surg Oncol; 2024 Mar; 31(3):2012-2013. PubMed ID: 37980705
[No Abstract] [Full Text] [Related]
20. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
